Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy

Inclusion Criteria:

• Participants must have an AHI of 15 or higher on polysomnography (PSG) at Day 1before randomization.

• Body Mass Index (BMI) of 27 kg/m^2 or more at the time of screening.

• History of at least one unsuccessful attempt at weight loss through diet andexercise.

• Participants must not have used PAP therapy for at least 4 weeks before screening,are unwilling/unable to use PAP, and do not plan to use PAP therapy during thestudy.

Exclusion Criteria:

• Individuals who have had any previous or planned upper airway surgery for sleepapnea or major ear, nose, or throat surgery.

• Those with significant craniofacial abnormalities that may affect breathing atscreening.

• Participants diagnosed with Central Apnea with a percentage of centralapneas/hypopneas of 50% or more, or those diagnosed with Cheyne Stokes Respiration.

• Active device treatment of OSA (eg, PAP, oral appliances), or other treatments, thatin the opinion of the investigator, may interfere with study outcomes, unlesswilling to stop treatment at screening and throughout the study.

• Individuals with respiratory diseases like obesity hypoventilation syndrome ordaytime hypercapnia, neuromuscular diseases or other conditions that could interferewith the trial results, according to the investigator's opinion.